عرض بسيط للتسجيلة

المؤلفAl-Badriyeh, Daoud
المؤلفLiew, Danny
المؤلفStewart, Kay
المؤلفKong, David C. M.
تاريخ الإتاحة2015-11-05T10:11:50Z
تاريخ النشر2012
اسم المنشورMycoses
الاقتباسAl-Badriyeh, D., Liew, D., Stewart, K. and Kong, D. C. M. (2012), Pharmacoeconomic analysis of voriconazole vs. caspofungin in the empirical antifungal therapy of febrile neutropenia in Australia. Mycoses, 55: 244–256.
الرقم المعياري الدولي للكتاب1439-0507
معرّف المصادر الموحدhttp://dx.doi.org/10.1111/j.1439-0507.2011.02074.x
معرّف المصادر الموحدhttp://hdl.handle.net/10576/3691
الملخصIn two major clinical trials, voriconazole and caspofungin were recommended as alternatives to liposomal amphotericin B for empirical use in febrile neutropenia. This study investigated the health economic impact of using voriconazole vs. caspofungin in patients with febrile neutropenia. A decision analytic model was developed to measure downstream consequences of empirical antifungal therapy. Clinical outcomes measured were success, breakthrough infection, persistent base-line infection, persistent fever, premature discontinuation and death. Treatment transition probabilities and patterns were directly derived from data in two relevant randomised controlled trials. Resource use was estimated using an expert clinical panel. Cost inputs were obtained from latest Australian sources. The analysis adopted the perspective of the Australian hospital system. The use of caspofungin led to a lower expected mean cost per patient than voriconazole (AU$40 558 vs. AU$41 356), with a net cost saving of AU$798 (1.9%) per patient. Results were most sensitive to the duration of therapy and the alternative therapy used post-discontinuation. In uncertainty analysis, the cost associated with caspofungin is less than that with voriconazole in 65.5% of cases. This is the first economic evaluation of voriconazole vs. caspofungin for empirical therapy. Caspofungin appears to have a higher probability of having cost-savings than voriconazole for empirical therapy. The difference between the two medications does not seem to be statistically significant however.
اللغةen
الناشرBlackwell Publishing Ltd
الموضوعCost-benefit
الموضوعeconomic
الموضوعmodel
الموضوعempiric
الموضوعvoriconazole
الموضوعcaspofungin
العنوانPharmacoeconomic analysis of voriconazole vs. caspofungin in the empirical antifungal therapy of febrile neutropenia in Australia
النوعArticle
رقم العدد3
رقم المجلد55


الملفات في هذه التسجيلة

الملفاتالحجمالصيغةالعرض

لا توجد ملفات لها صلة بهذه التسجيلة.

هذه التسجيلة تظهر في المجموعات التالية

عرض بسيط للتسجيلة